Premium
Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016
Author(s) -
Otani Yasushi,
Kijima Takashi,
Kohmo Satoshi,
Oishi Shinya,
Minami Toshiyuki,
Nagatomo Izumi,
Takahashi Ryo,
Hirata Haruhiko,
Suzuki Mayumi,
Inoue Koji,
Takeda Yoshito,
Kida Hiroshi,
Tachibana Isao,
Fujii Nobutaka,
Kumanogoh Atsushi
Publication year - 2012
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2012.08.011
Subject(s) - cancer research , cancer , cxcr4 , cell , lung , lung cancer , chemistry , medicine , pathology , biochemistry , receptor , chemokine
CXCL12 is a chemokine essential for the organ‐specific spread of a variety of cancers including small cell lung cancer (SCLC). Here, we examined the anti‐metastatic efficacy of TF14016, a small peptidic inhibitor of CXCL12 receptor CXCR4, in SCLC. Treatment of mice with TF14016 significantly suppressed pulmonary metastases of CXCR4‐expressing SCLC in size and number. Furthermore, histological examination revealed that the expression of vascular endothelial cell growth factor and the density of CD31‐positive microvessels in metastatic foci were both significantly reduced in TF14016‐treated mice. Collectively, CXCR4 could be an attractive target for anti‐metastatic and anti‐angiogenic therapy in SCLC.